A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

Summary

This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC

Eligibility

Inclusion Criteria:

1. Males and/or females over age 18
2. Histologically and/or cytologically documented local advanced or metastatic NSCLC .
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
4. Expected survival \>=3 months.
5. Signed informed consent form.

Exclusion Criteria:

1. Known uncontrolled or symptomatic central nervous system metastatic disease.
2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0).
3. Inadequate organ or bone marrow function.
4. Pregnant or breast-feeding woman.
5. Known allergies, hypersensitivity, or intolerance to SSGJ-706

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Conditions3

Interventions4

Related trials

• Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer — The Netherlands Cancer Institute
• Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer — Karolinska University Hospital
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer — AstraZeneca
• Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase — Fudan University
• SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC — West China Hospital
• Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies — Sichuan University
• Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI — Betta Pharmaceuticals Co., Ltd.
• Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors — Vivace Therapeutics, Inc

Browse More Trials